Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473778 · ClinicalTrials.gov registry record
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
A clinical trial, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- 3,000
- Enrollment target
NCT07473778 is a clinical trial that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 3,000 participants.
The verdict
NCT07473778 is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
Study Summary
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
Interventions
- DRUG Lenacapavir Injection
- DRUG Lenacapavir Tablet
- DRUG Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
- DRUG Cabotegravir (CAB)
- DRUG Emtricitabine/tenofovir alafenamide (F/TAF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2029-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07473778
The ClinicalTrials.gov registry entry for NCT07473778 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Lenacapavir Injection is the first listed.
NCT07473778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07473778 about?
NCT07473778 is a clinical study titled "Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention". The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine c...
What is the current status of trial NCT07473778?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2026-03-17. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07473778?
The interventions under investigation include: Lenacapavir Injection (DRUG), Lenacapavir Tablet (DRUG), Emtricitabine/tenofovir disoproxil fumarate (F/TDF) (DRUG), Cabotegravir (CAB) (DRUG), Emtricitabine/tenofovir alafenamide (F/TAF) (DRUG).
Who is sponsoring clinical trial NCT07473778?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.